Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...

Read More

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Posted by on Mar 12, 2019 in Leukemia | 0 comments

In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...

Read More

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL.  Some background...

Read More

Evaluating ibrutinib plus nivolumab for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Feb 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...

Read More

Is BRESHAP an effective treatment for relapsed and unresponsive Hodgkin lymphoma?

Posted by on Feb 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma.  This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More

How effective and safe is pomalidomide in relapsed/refractory multiple myeloma?

Posted by on Jan 17, 2019 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of pomalidomide (Pomalyst) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM) in a real-life setting. The authors concluded that this treatment is safe and effective in these patients.  Some background Multiple myeloma...

Read More

Venetoclax-rituximab combination improves survival in patients with unresponsive and relapsed chronic lymphocytic leukemia

Posted by on Jan 5, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...

Read More

Evaluating ixazomib, cyclophosphamide and dexamethasone treatment for relapsed/refractory multiple myeloma

Posted by on Dec 22, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...

Read More